Carol Jolly
University of Liverpool(GB)
Publications by Year
Research Areas
Mitochondrial Function and Pathology, Cancer Immunotherapy and Biomarkers, Metabolomics and Mass Spectrometry Studies, Metabolism and Genetic Disorders, Drug-Induced Adverse Reactions
Most-Cited Works
- → Transcriptional Repression of E-Cadherin by Human Papillomavirus Type 16 E6(2012)85 cited
- → The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity(2018)42 cited
- → Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity(2021)35 cited
- → Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis(2020)27 cited
- → Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes(2007)25 cited
- → T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab(2021)23 cited
- → Acute Metabolic Switch Assay Using Glucose/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity(2019)22 cited
- → TNF-α‒Mediated Keratinocyte Expression and Release of Matrix Metalloproteinase 9: Putative Mechanism of Pathogenesis in Stevens‒Johnson Syndrome/Toxic Epidermal Necrolysis(2022)21 cited
- → Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma(2021)10 cited
- → TNF‐α induced extracellular release of keratinocyte high‐mobility group box 1 in Stevens‐Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis(2023)9 cited